Sreelakshmi Ravula Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Associate Professor
faculty
Internal Medicine, College of Medicine
Research Areas
Biography and Research Information
OverviewAI-generated summary
Sreelakshmi Ravula's research focuses on critical care medicine, with a particular emphasis on acute kidney injury (AKI) and its management. Her work investigates predictors of adverse outcomes in patients with AKI, including studies on urinary complement C3 and vitamin D-binding protein. Ravula also explores specific clinical challenges, such as unresolving hypokalemia and dialysis-associated reactions.
Her publications demonstrate an interest in various aspects of nephrology and critical care, including the role of acidosis in chronic kidney and liver disease, and interventions for AKI, such as targeted intra-abdominal pressure reduction. Ravula collaborates with researchers at the University of Arkansas for Medical Sciences, including Joseph H. Holthoff and Omar Dodin, on shared publications. Her scholarship metrics include an h-index of 3, with 8 total publications cited 735 times.
Metrics
- h-index: 3
- Publications: 8
- Citations: 735
Selected Publications
-
Perfusion Under Pressure: Reversing Anuric AKI with Targeted Intra-Abdominal Pressure (IAP) Reduction (2025)
-
A Case of Unresolving Hypokalemia (2024)
-
A Curious Case of Dialysis-Associated Reaction (2024)
-
Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery (2024)
-
No Good Deed: Acidosis in Chronic Kidney and Liver Disease (2023)
Grants & Funding
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (IRB 262333) Travere Therapeutics Principal Investigator
- No FP attached Retrophin, Inc. - Pass Through: IQVIA, Inc. Principal Investigator
- Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (IRB 274955) NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: Benaroya Research Institute at Virginia Mason Principal Investigator
- Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (IRB 274955) NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: Benaroya Research Institute at Virginia Mason Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics